Voodoo in NOLA? Say it ain’t so!

A few years ago long before the advent of the KRASG12C inhibitors, a scientist once drolly stated to me that trying to drug RAS, and KRAS in particular, was akin to the med-chemist’s version of voodoo. Hah!

Fast forward a few years to AACR in New Orleans and we have a veritable feast of RAS targeted agents now coming through quite a few company pipelines in all shapes and forms from covalent and non-covalent inhibitors to molecular glues, and even bifunctional degraders.

Some voodoo, man.

In this review, we look carefully at three different companies (including biotechs and big pharma) who are actively developing various inhibitors in the RAS niche with early stage developments and look at what’s coming along behind Amgen and Mirati… the first isn’t always the best in the long run, so what should we be looking at and learning from in the next tranche?

BSB subscribers can read our latest conference coverage from AACR plus commentary and analysis – you can either log-in or click to access.

This content is restricted to subscribers

Posted by